Payment overview · 2025
General Payments
$387.15
22 reported records · 10 companies
Healthcare provider profile · identity verified
Shawn Beckemeyer, MD
Allopathic & Osteopathic Physicians|Family Medicine · COULTERVILLE, IL · NPI 1023075264
Verified facts
What the public records show
CMS Open Payments records show Shawn Beckemeyer, MD received $387.15 in general payments during 2025 across 22 reported records.
Novo Nordisk Inc accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.78 | 20.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.50 | 20.8% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $71.22 | 18.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.52 | 10.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.52 | 7.9% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $24.28 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.63 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.30 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.88 | 3.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.52 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $387.15 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $71.22 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.41 | 4 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.52 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 62 |
| Gabapentin | Gabapentin | 236 | 41 |
| Lisinopril | Lisinopril | 222 | 57 |
| Montelukast Sodium | Montelukast Sodium | 169 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 34 |
| Metformin Hcl | Metformin Hcl | 155 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 37 |
| Meloxicam | Meloxicam | 128 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 27 |
| Trazodone Hcl | Trazodone Hcl | 126 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 125 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 119 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 116 | 19 |
| Prednisone | Prednisone | 108 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 31 |
| Losartan Potassium | Losartan Potassium | 103 | 23 |
| Omeprazole | Omeprazole | 102 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 20 |
| Furosemide | Furosemide | 92 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 17 |
| Potassium Chloride | Potassium Chloride | 89 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 29 |
| Alendronate Sodium | Alendronate Sodium | 75 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 17 |
| Ozempic | Semaglutide | 65 | 13 |
| Buspirone Hcl | Buspirone Hcl | 63 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Simvastatin | Simvastatin | 63 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 12 |
| Jardiance | Empagliflozin | 56 | 13 |
| Trulicity | Dulaglutide | 56 | 11 |
| Ezetimibe | Ezetimibe | 55 | 15 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Alprazolam | Alprazolam | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | suppressed |
| Eliquis | Apixaban | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | 14 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 16 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 13 |
| Atenolol | Atenolol | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lorazepam | Lorazepam | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Naproxen | Naproxen | 24 | 11 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $387.15 · 22 records | Novo Nordisk Inc | BEXSERO, FARXIGA, JARDIANCE, MOUNJARO, NEXPLANON, OTEZLA, PEDIARIX, REPATHA, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error